ZA200305569B - Compounds and compositions for delivering active agents. - Google Patents
Compounds and compositions for delivering active agents. Download PDFInfo
- Publication number
- ZA200305569B ZA200305569B ZA200305569A ZA200305569A ZA200305569B ZA 200305569 B ZA200305569 B ZA 200305569B ZA 200305569 A ZA200305569 A ZA 200305569A ZA 200305569 A ZA200305569 A ZA 200305569A ZA 200305569 B ZA200305569 B ZA 200305569B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- active agent
- insulin
- hormone
- calcitonin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 86
- 239000013543 active substance Substances 0.000 title claims description 83
- 239000000203 mixture Substances 0.000 title claims description 53
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- -1 heparinocids Polymers 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 108090001061 Insulin Proteins 0.000 claims description 20
- 102000004877 Insulin Human genes 0.000 claims description 20
- 229940125396 insulin Drugs 0.000 claims description 20
- 239000000122 growth hormone Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- ITIXDWVDFFXNEG-JHOUSYSJSA-N olcegepant Chemical compound C([C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCN(CC1)C=1C=CN=CC=1)NC(=O)N1CCC(CC1)N1C(NC2=CC=CC=C2C1)=O)C1=CC(Br)=C(O)C(Br)=C1 ITIXDWVDFFXNEG-JHOUSYSJSA-N 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 12
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 12
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 12
- 229920000669 heparin Polymers 0.000 claims description 12
- 229960001319 parathyroid hormone Drugs 0.000 claims description 12
- 239000000199 parathyroid hormone Substances 0.000 claims description 12
- 108060001064 Calcitonin Proteins 0.000 claims description 10
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 10
- 102000055006 Calcitonin Human genes 0.000 claims description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 102000003951 Erythropoietin Human genes 0.000 claims description 8
- 108090000394 Erythropoietin Proteins 0.000 claims description 8
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 8
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 8
- 229940105423 erythropoietin Drugs 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 239000003055 low molecular weight heparin Substances 0.000 claims description 8
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 8
- 229960004015 calcitonin Drugs 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 6
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 5
- 229960000958 deferoxamine Drugs 0.000 claims description 5
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000003488 releasing hormone Substances 0.000 claims description 5
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 4
- 229940126657 Compound 17 Drugs 0.000 claims description 4
- 101800000414 Corticotropin Proteins 0.000 claims description 4
- 108010029961 Filgrastim Proteins 0.000 claims description 4
- 102000004547 Glucosylceramidase Human genes 0.000 claims description 4
- 108010017544 Glucosylceramidase Proteins 0.000 claims description 4
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 4
- 102000000589 Interleukin-1 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 102400000050 Oxytocin Human genes 0.000 claims description 4
- 101800000989 Oxytocin Proteins 0.000 claims description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 4
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 4
- 230000001746 atrial effect Effects 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 4
- 229940125773 compound 10 Drugs 0.000 claims description 4
- 229940126214 compound 3 Drugs 0.000 claims description 4
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 4
- 229960000258 corticotropin Drugs 0.000 claims description 4
- 229960004177 filgrastim Drugs 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229940047124 interferons Drugs 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 4
- 229960001723 oxytocin Drugs 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 3
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
- 229930105110 Cyclosporin A Natural products 0.000 claims description 3
- 108010036949 Cyclosporine Proteins 0.000 claims description 3
- 229920000045 Dermatan sulfate Polymers 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 3
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 3
- 102000018997 Growth Hormone Human genes 0.000 claims description 3
- 108010051696 Growth Hormone Proteins 0.000 claims description 3
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 3
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims description 3
- 229920001499 Heparinoid Polymers 0.000 claims description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 101710142969 Somatoliberin Proteins 0.000 claims description 3
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 3
- 108010059993 Vancomycin Proteins 0.000 claims description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 3
- 108010004977 Vasopressins Proteins 0.000 claims description 3
- 102000002852 Vasopressins Human genes 0.000 claims description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 229960001265 ciclosporin Drugs 0.000 claims description 3
- 229940125797 compound 12 Drugs 0.000 claims description 3
- 229940126543 compound 14 Drugs 0.000 claims description 3
- 229940125758 compound 15 Drugs 0.000 claims description 3
- 229940126142 compound 16 Drugs 0.000 claims description 3
- 229940125782 compound 2 Drugs 0.000 claims description 3
- 229940125898 compound 5 Drugs 0.000 claims description 3
- 229960000265 cromoglicic acid Drugs 0.000 claims description 3
- 229930182912 cyclosporin Natural products 0.000 claims description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 3
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 3
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 3
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 3
- 239000002554 heparinoid Substances 0.000 claims description 3
- 229940025770 heparinoids Drugs 0.000 claims description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 235000013772 propylene glycol Nutrition 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- 229960003165 vancomycin Drugs 0.000 claims description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 3
- 229960003726 vasopressin Drugs 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 108010068072 salmon calcitonin Proteins 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims 6
- 102000013275 Somatomedins Human genes 0.000 claims 3
- 101001011741 Bos taurus Insulin Proteins 0.000 claims 2
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims 2
- 108010005991 Pork Regular Insulin Proteins 0.000 claims 2
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims 2
- 229940045644 human calcitonin Drugs 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- 230000002608 insulinlike Effects 0.000 claims 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 claims 1
- JDJALSWDQPEHEJ-LMVCGNDWSA-N x4853 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JDJALSWDQPEHEJ-LMVCGNDWSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 78
- 239000000243 solution Substances 0.000 description 65
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 229940124447 delivery agent Drugs 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 16
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
- 239000011347 resin Substances 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000000921 elemental analysis Methods 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 11
- 235000002639 sodium chloride Nutrition 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 6
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- 229960000281 trometamol Drugs 0.000 description 5
- 238000003828 vacuum filtration Methods 0.000 description 5
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 125000003816 2-hydroxybenzoyl group Chemical group OC1=C(C(=O)*)C=CC=C1 0.000 description 3
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108010039627 Aprotinin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 3
- 229960001076 chlorpromazine Drugs 0.000 description 3
- 150000001860 citric acid derivatives Chemical class 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 210000004283 incisor Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 229960000581 salicylamide Drugs 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- DSGKWFGEUBCEIE-UHFFFAOYSA-N (2-carbonochloridoylphenyl) acetate Chemical compound CC(=O)OC1=CC=CC=C1C(Cl)=O DSGKWFGEUBCEIE-UHFFFAOYSA-N 0.000 description 2
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 description 2
- NVWSLNRSPZAQOK-UHFFFAOYSA-N 3,4-dibromo-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C(Br)=C1O NVWSLNRSPZAQOK-UHFFFAOYSA-N 0.000 description 2
- CNJGWCQEGROXEE-UHFFFAOYSA-N 3,5-Dichlorosalicylicacid Chemical compound OC(=O)C1=CC(Cl)=CC(Cl)=C1O CNJGWCQEGROXEE-UHFFFAOYSA-N 0.000 description 2
- UIKUBYKUYUSRSM-UHFFFAOYSA-N 3-morpholinopropylamine Chemical compound NCCCN1CCOCC1 UIKUBYKUYUSRSM-UHFFFAOYSA-N 0.000 description 2
- CAKJEDBOIMYCHP-UHFFFAOYSA-N 8-(dimethylamino)octan-1-ol Chemical compound CN(C)CCCCCCCCO CAKJEDBOIMYCHP-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 102000014429 Insulin-like growth factor Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- DWGFRPGBXOYFAH-UHFFFAOYSA-N acetyl 5-chloro-2-hydroxybenzoate Chemical compound CC(=O)OC(=O)C1=CC(Cl)=CC=C1O DWGFRPGBXOYFAH-UHFFFAOYSA-N 0.000 description 2
- 229940068372 acetyl salicylate Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- OAYRYNVEFFWSHK-UHFFFAOYSA-N carsalam Chemical compound C1=CC=C2OC(=O)NC(=O)C2=C1 OAYRYNVEFFWSHK-UHFFFAOYSA-N 0.000 description 2
- 229950004289 carsalam Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- JSPCTNUQYWIIOT-UHFFFAOYSA-N piperidine-1-carboxamide Chemical compound NC(=O)N1CCCCC1 JSPCTNUQYWIIOT-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940108519 trasylol Drugs 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- CAPCBAYULRXQAN-UHFFFAOYSA-N 1-n,1-n-diethylpentane-1,4-diamine Chemical compound CCN(CC)CCCC(C)N CAPCBAYULRXQAN-UHFFFAOYSA-N 0.000 description 1
- LRXFKKPEBXIPMW-UHFFFAOYSA-N 2-(9h-fluoren-2-yl)propanoic acid Chemical compound C1=CC=C2C3=CC=C(C(C(O)=O)C)C=C3CC2=C1 LRXFKKPEBXIPMW-UHFFFAOYSA-N 0.000 description 1
- CDSQZEHAJSIDTE-UHFFFAOYSA-N 2-chlorooxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OCl CDSQZEHAJSIDTE-UHFFFAOYSA-N 0.000 description 1
- DHZVWQPHNWDCFS-UHFFFAOYSA-N 2-hydroxy-3,5-diiodobenzoic acid Chemical compound OC(=O)C1=CC(I)=CC(I)=C1O DHZVWQPHNWDCFS-UHFFFAOYSA-N 0.000 description 1
- VTUVJKMXTRXVIQ-UHFFFAOYSA-N 2-hydroxy-4-(6-morpholin-4-ylhexyl)benzamide Chemical compound C1=C(O)C(C(=O)N)=CC=C1CCCCCCN1CCOCC1 VTUVJKMXTRXVIQ-UHFFFAOYSA-N 0.000 description 1
- WUVHUOXHRRCPEE-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;pentane Chemical compound CCCCC.OC(=O)CC(O)(C(O)=O)CC(O)=O WUVHUOXHRRCPEE-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- NKBASRXWGAGQDP-UHFFFAOYSA-N 5-chlorosalicylic acid Chemical compound OC(=O)C1=CC(Cl)=CC=C1O NKBASRXWGAGQDP-UHFFFAOYSA-N 0.000 description 1
- FCMCSZXRVWDVAW-UHFFFAOYSA-N 6-bromo-1-hexanol Chemical compound OCCCCCCBr FCMCSZXRVWDVAW-UHFFFAOYSA-N 0.000 description 1
- FVCQUNUNTADJFP-UHFFFAOYSA-N 6-morpholin-4-ylhexan-1-ol Chemical compound OCCCCCCN1CCOCC1 FVCQUNUNTADJFP-UHFFFAOYSA-N 0.000 description 1
- GMXIEASXPUEOTG-UHFFFAOYSA-N 8-bromooctan-1-ol Chemical compound OCCCCCCCCBr GMXIEASXPUEOTG-UHFFFAOYSA-N 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- GEOSRCSYJBCCHE-UHFFFAOYSA-N C(CC(O)(C(=O)O)CC(=O)O)(=O)O.OC1=C(C(=O)NC(C)CCCN(CC)CC)C=CC=C1.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C)N(CCCCC(C)NC(C1=C(C=CC=C1)O)=O)CC Chemical compound C(CC(O)(C(=O)O)CC(=O)O)(=O)O.OC1=C(C(=O)NC(C)CCCN(CC)CC)C=CC=C1.C(CC(O)(C(=O)O)CC(=O)O)(=O)O.C(C)N(CCCCC(C)NC(C1=C(C=CC=C1)O)=O)CC GEOSRCSYJBCCHE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- 206010012186 Delayed delivery Diseases 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- FLKRPKPMPGGNLT-UHFFFAOYSA-N OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCCC(C)NC(=O)c1cc(Cl)ccc1O Chemical compound OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCCC(C)NC(=O)c1cc(Cl)ccc1O FLKRPKPMPGGNLT-UHFFFAOYSA-N 0.000 description 1
- HTEFONPXERUZIG-UHFFFAOYSA-N OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1cc(Cl)ccc1O Chemical compound OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1cc(Cl)ccc1O HTEFONPXERUZIG-UHFFFAOYSA-N 0.000 description 1
- XOFYPNPXVHMLDA-UHFFFAOYSA-N OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1ccccc1O Chemical compound OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCNC(=O)c1ccccc1O XOFYPNPXVHMLDA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 1
- XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 daptomycin Drugs 0.000 description 1
- RMKNCYHVESPYFD-UHFFFAOYSA-N decan-1-amine;hydrochloride Chemical compound [Cl-].CCCCCCCCCC[NH3+] RMKNCYHVESPYFD-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960005051 fluostigmine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940069330 human zinc insulin Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- PHFDTSRDEZEOHG-UHFFFAOYSA-N hydron;octan-1-amine;chloride Chemical compound Cl.CCCCCCCCN PHFDTSRDEZEOHG-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- RSCPAUDUIFTNMJ-UHFFFAOYSA-N n-(12-aminododecyl)-2-hydroxybenzamide;hydron;chloride Chemical compound Cl.NCCCCCCCCCCCCNC(=O)C1=CC=CC=C1O RSCPAUDUIFTNMJ-UHFFFAOYSA-N 0.000 description 1
- QVNCMEAOBCFURZ-UHFFFAOYSA-N n-(8-aminooctyl)-2-hydroxy-4-methoxybenzamide;hydron;chloride Chemical compound Cl.COC1=CC=C(C(=O)NCCCCCCCCN)C(O)=C1 QVNCMEAOBCFURZ-UHFFFAOYSA-N 0.000 description 1
- ALOJBBWVRVRSJL-UHFFFAOYSA-N n-(9-aminononyl)-2-hydroxybenzamide Chemical compound NCCCCCCCCCNC(=O)C1=CC=CC=C1O ALOJBBWVRVRSJL-UHFFFAOYSA-N 0.000 description 1
- OOCMLHYCTKPFDJ-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-2-hydroxy-4-methoxybenzamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(OC)C=C1O OOCMLHYCTKPFDJ-UHFFFAOYSA-N 0.000 description 1
- UIZVXHYSWVPILS-UHFFFAOYSA-N n-[8-(dimethylamino)octyl]-2-hydroxybenzamide;hydrochloride Chemical compound Cl.CN(C)CCCCCCCCNC(=O)C1=CC=CC=C1O UIZVXHYSWVPILS-UHFFFAOYSA-N 0.000 description 1
- HSMQPTZWOJRCEF-UHFFFAOYSA-N n-[[4-(dimethylamino)phenyl]methyl]-2-hydroxybenzamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C1=CC=CC=C1O HSMQPTZWOJRCEF-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000020588 necrotizing soft tissue infection Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 102220006493 rs80338873 Human genes 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
BE ©. 2003/55689
COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
. This application claims the benefit of U.S. Provisional
Application No. 60/272,726, filed March 1, 2001; U.S. : Provisional Application No. 60/314,783, filed August 24, 2001; and U.S. Provisional Application No. 60/323,139, filed
September 17, 2001, all of which are hereby incorporated by reference.
The present invention relates to compounds for delivering ’ active agents, such as biologically or chemically active agents, to a target. These compounds are well suited for forming non-covalent mixtures with active agents for oral, intracolonic, pulmonary, and other routes of administration to animals. Methods for the preparation and administration of such compositions are also disclosed.
Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, the environment of the target for delivery, and/or the target itself.
Biologically and chemically active agents are particularly vulnerable to such barriers.
In the delivery to animals of biologically active and chemically active pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin, lipid bi-layers and various organ membranes that are relatively impermeable to certain active
© WO 02/069937 . PCT/US02/06610 agents but must be traversed before reaching a target, such as the circulatory system. Chemical barrier: include, but are not limited to, pH.variations in the gastrointestinal (GI) tract and degrading enzymes.
These barriers are of particular significance in the ) design of oral delivery systems. Oral delivery of many biologically or chemically active agents would be the route of chojce for administration to animals if not for biological, chemical, and physical barriers. Among the numerous agents which are not typically amenable to oral administration are biologically or ci -=mically active peptides, such as calcitonin and insulin; polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents may be rapidly rendered ineffective or destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, and the : like. In addition, the size and structure of macromolecular drugs may prohibit absorption.
Earlier methods for orally administering vulnerable pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation. Liposomes have also been described as drug delivery systems for insulin and heparin. However, broad spectrum use of such drug delivery systems is precluded because: (1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. : active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life; (4) the systems are ‘
difficult to manufacture; (5) the systems fail to protect the active agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent. ’ 5 Proteinoid microspheres have been used to deliver pharmaceuticals. See, for example, U.S. Patent Nos. } 5,401,516; 5,443,841; and Re. 35,862. In addition, certain modified amino acids have been used to deliver pharmaceuticals. See, for example, U.S. Patent Nos. 5,629,020; 5,643,957; 5,766,633; 5,776,888; and 5,866,536.
More recently, a polymer has been conjugated to a modified amino acid or a derivative thereof via a linkage group to provide for polymeric delivery agents. The modified polymer may be any polymer, but preferred polymers include, but are not limited to, polyethylene glycol (PEG), and derivatives thereof. See, for example, International Patent :
Publication No. WO 00/40203.
However, there is still a need for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad range of active agents by various routes.
The present invention provides compounds and compositions which facilitate the delivery of active agents. Delivery agent compounds of the present invention include those having the following formulas:
OH ©O ( : H cl ’
Compound 1 } '
OH O
CF
H
Compound 2
OH © dd
H
Compound 3
OH O
N
N~ .
Compound 4
OH 0 3
OF
H
Compound 5
OH OO J dd
N
Oy ~~
H
. Compound 6
IP! IK (r N._~
H
Cl
Compound 7
OH O )
Cy
H ~_
Compound 8
OH O
Cy cr
H
LG) Compound 9
OH O of ENN NAN =
N
H
} Compound 10
OH O
NH, CI” oon]
H
~o , . Compound 11 : OH O
RSA RaT
H \=/
Br : Compound 12
OH O
REARaE
H \—/
Cl
Compound 13
OH O
ICRA.
H \—/
I
Compound 14 oH O
Br NSTI
L_o
Br
Compound 15
-OH O . ~
Cl NN" 0) ae
Cl
Compound 16 0 clr
OH
Compound 17 5 . .
J
OH O
NNSA NH, 0) } Compound 18 and salts thereof. Mixtures of these delivery agent compounds may also be used to facilitate the delivery of active agents.
The invention also provides a composition comprising at least one of the delivery agent compounds of the formulas above, and at least one active agent. These compositions deliver active agents to selected biological systems in increased or improved bioavailability of the active agent compared to administration of the active agent without the : delivery agent compound.
Also provided are dosage unit forms comprising the compositions. The dosage unit may be in the form of a liquid or a solid, such as a tablet, capsule or particle, including a powder or sachet.
Another embodiment is a method for administering an active agent to an animal in need of the active agent, by administering a composition comprising at least one of the delivery agent compounds of the formula above and the active agent to the animal. Preferred routes of administration include the oral, intracolonic and pulmonary routes.
Yet another embodiment is a method of treating a disease or for achieving a desired physiological effect in an animal by administering the composition of the present invention.
Yet another embodiment is a method of preparing a composition of the present invention by mixing at least one delivery agent compound of the formula above, and at least one active agent.
Delivery Agent Compounds }
The terms “alkyl” and “alkenyl” as used herein include linear and branched alkyl and alkenyl substituents, respectively.
The delivery agent compounds may be in the form of the free base or salts thereof. Suitable salts include, but are not limited to, organic and inorganic salts, for example, hydrochloride, ammonium, acetate, citrate, halide, hydroxide, sulfate, nitrate, phosphate, alkoxy, perchlorate, tetrafluoroborate, carboxylate, mesylate, fumerate, malonate, succinate, tartrate, acetate, gluconate, and maleate salts.
The salts may also be solvates, including ethanol solvates, and hydrates. The mesylate salt can be formed by reacting the free base of the delivery agent compound with methanesulfonic acid. ’ . Salts of the delivery agent compounds of the present invention may be prepared by methods known in the art. For )
example, citrate salts may be prepared in ethanol, toluene and citric acid. The salts may also be solvates, including + ethanol solvates, and hydrates. :
The delivery agent compound may be purified by ’ 5 recrystallization or by fractionation on one or more solid chromatographic supports, alone or linked in tandem. Suitable ) recrystallization solvent systems include, but are not limited to, ethanol, water, heptane, ethyl acetate, acetonitrile, : methanol, and tetrahydrofuran (THF) and mixtures thereof.
Fractionation may be performed on a suitable chromatographic support such as alumina, using methanol/n-propanol mixtures as the mobile phase; reverse phase chromatography using trifluoroacetic acid/acetonitrile mixtures as the mobile phase; and jon exchange chromatography using water or an appropriate buffer as the mobile phase. When anion exchange chromatography is performed, preferably a 0-500 mM sodium : chloride gradient is employed.
The delivery agent may contain a polymer conjugated to it by a linkage group selected from the group consisting of -
NHC (O)NH-, -C(O)NH-,-NHC(O), -00C-, -COO-, -NHC(O)O-, ~-
OC (O)NH-, -CH;NH -NHCH,-, -CH,;NHC (0) 0O-, -OC(O)NHCH,—,-
CH,NHCOCH,0-, —-OCH,C (O)NHCH,-, - NHC(O)CH,O0-, -OCH,C(O)NH~, -NH- , —0—, and carbon-carbon bond, with the proviso that the polymeric delivery agent is not a polypeptide or polyamino acid. The polymer may be any polymer including, but not limited to, alternating copolymers, block copolymers and random copolymers, which are safe for use in mammals.
Preferred polymers include, but are not limited to, polyethylene; polyacrylates; polymethacrylates; ’ : 30 poly(oxyethylene); poly(propylene); polypropylene glycol; polyethylene glycol (PEG); and derivatives thereof and combinations thereof. The molecular weight of the polymer typically ranges from about 100 to about 200,000 daltons. The molecular weight of the polymer preferably ranges from about 200 to about 10,000 daltons. In one embodiment, the molecular weight of the polymer ranges from about 200 to about 600 daltons and more preferably ranges from about 300 to about 550 daltons.
Active Agents
Active agents suitable for use in the present invention include biologically active agents and chemically active agents, including, but not limited to, pesticides, pharmacological agents, and therapeutic agents. Suitable active agents include those that are rendered less effective, ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes and the like. Also included as suitable active agents are those macromolecular agents whose . physiochemical characteristics, such as, size, structure or charge, prohibit or impede absorption when dosed orally.
For example, biologically or chemically active agents suitable for use in the present invention include, but are not limited to, proteins; polypeptides; peptides; hormones; polysaccharides, and particularly mixtures of muco- polysaccharides; carbohydrates; lipids; small polar organic molecules (i.e. polar organic molecules having a molecular weight of 500 daltons or less); other organic compounds ; and particularly compounds which by themselves do not pass (or which pass only a fraction of the administered dose) through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro- intestinal tract; or any combination thereof.
Further examples include, but are not limited to, the . following, including synthetic, natural or recombinant sources thereof: growth hormones, including human growth- hormones . (hGH), recombinant human growth hormones (rhGH), bovine growth -— 1 0 -
. hormones, and porcine growth hormones; growth hormone releasing hormones; growth hormone releasing factor, interferons, including a, B and vy; interleukin-1; interleukin- 2; insulin, including porcine, bovine, human, and human 5S recombinant, optionally having counter ions including zinc, sodium, calcium and ammonium; insulin-like growth factor, including IGF-1; heparin, including unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin and ultra low molecular weight heparin; calcitonin, including salmon, eel, porcine and human; erythropoietin; atrial naturetic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; leutinizing-hormone-releasing~hormone;
follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO) ; bisphosphonates, including alendronate, tiludronate,
etidronate, clodronate, pamidronate, olpadronate, and incadronate; parathyroid hormone (PTH), including its fragments; anti-migraine agents such as BIBN-4096BS and other calcitonin gene-related proteins antagonists; antimicrobials, including antibiotics, anti-bacterials and anti-fungal agents;
vitamins; analogs, fragments, mimetics or polyethylene glycol (PEG) -modified derivatives of these compounds; or any combination thereof.
Non-limiting examples of antibiotics include gram-positive acting, bacteriocidal, lipopeptidal and cyclic peptidal antibiotics, such as daptomycin and analogs thereof.
Delivery systems
The composition of the present invention comprises one or . more delivery agent compounds of the present invention, and one or more active agents. In one embodiment, one or more of the delivery agent compounds, or salts of these compounds, or ' poly amino acids or peptides of which these compounds or salts form one or more of the units thereof, may be used as a delivery agent by mixing with the active agent prior to administration to form an administration composition. i0 The administration compositions may be in the form of a liquid. The solution medium may be water (for example, for salmon calcitonin, parathyroid hormone, and erythropoietin), © 25% aqueous propylene glycol (for example, for heparin) and phosphate buffer (for example, for rhGH). Other dosing vehicles include polyethylene glycol. Dosing solutions may be prepared by mixing a solution of the delivery agent compound : with a solution of the active agent, just prior to administration. Alternately, a solution of the delivery agent compound (or active agent) may be mixed with the solid form of the active agent (or delivery agent compound). The delivery agent compound and the active agent may also be mixed as dry powders. The delivery agent compound and the active agent can also be admixed during the manufacturing process.
The dosing solutions may optionally contain additives such as phosphate buffer salts, citric acid, glycols, or other dispersing agents. Stabilizing additives may be incorporated into the solution, preferably at a concentration ranging between about 0.1 and 20% (w/v).
In one embodiment, dosing solution containing BIBN-4096BS have a pH of less than 8. According to another embodiment, dosing solutions containing BIBN-4096BS have a pH of less than . 7.
The administration compositions may alternately be in the .
form of a solid, such as a tablet, capsule or particle, such as a powder or sachet. Solid dosage forms may be prepared by mixing the solid form of the compound with the solid form of the active agent. Alternately, a solid may be obtained from a : ’ 5 solution of compound and active agent by methods known in the art, such as freeze-drying (lyophilization), precipitation, : ) crystallization and solid dispersion.
The administration compositions of the present invention may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof. Other enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor. ’
The amount of active agent used in an administration composition of the present invention is an amount effective to accomplish the purpose of the particular active agent fox the : target indication. The amount of active agent in the compositions typically is a pharmacologically, biologically, therapeutically, or chemically effective amount. However, the amount can be less than that amount when the composition is used in a dosage unit form because the dosage unit form may contain a plurality of delivery agent compound/active agent compositions or may contain a divided pharmacologically, biologically, therapeutically, or chemically effective amount.
The total effective amount can then be administered in cumulative units containing, in total, an effective amount of the active agent.
The total amount of active agent to be used can be determined by methods known to those skilled in the art.
However, because the compositions of the invention may deliver : active agents more efficiently than compositions containing the active agent alone, lower amounts of biologically or chemically active agents than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and/or therapeutic effects.
The presently disclosed delivery agent compounds facilitate the delivery of biologically and chemically active ' agents, particularly in oral, intranasal, sublingual, intraduodenal, subcutaneous, buccal, intracolonic, rectal, vaginal, mucosal, pulmonary, transdermal, intradermal, parenteral, intravenous, intramuscular and ocular systems, as well as traversing the blood-brain barrier.
Dosage unit forms can also include any one or combination of excipients, diluents, disintegrants, lubricants, plasticizers, colorants, flavorants, taste-masking agents, sugars, sweeteners, salts, and dosing vehicles, including, but not limited to, water, 1,2-propane diol, ethanol, olive oil, or any combination thereof. )
The compounds and compositions of the subject invention are useful for administering biologically or chemically active agents to any animals, including but not limited to birds such as chickens; mammals, such as rodents, cows, pigs, dogs, cats, primates, and particularly humans; and insects.
The system is particularly advantageous for delivering chemically or biologically active agents that would otherwise be destroyed or rendered less effective by conditions encountered before the active agent reaches its target zone (i.e. the area in which the active agent of the delivery composition is to be released) and within the body of the : animal to which they are administered. Particularly, the ‘ compounds and compositions of the present invention are useful in orally administering active agents, especially those that are not ordinarily orally deliverable, or those for which . improved delivery is desired.
The compositions comprising the compounds and active :
agents have utility in the delivery of active agents to selected biological systems and in an increased or improved bicavailability of the active agent compared to administration of the active agent without the delivery agent. Delivery can ’ 5 be improved by delivering more active agent over a period of time, or in delivering active agent in a particular time ’ period (such as to effect quicker or delayed delivery), or in delivering the active agent at a specific time, or over a period of time (such as sustained delivery).
Another embodiment of the present invention is a method for the treatment or prevention of a disease or for achieving a desired physiological effect, such as those listed in the table below, in an animal by administering the composition of the present invention. Specific indications for active agents can be found in the Physicians’ Desk Reference (54% Ed., 2000,
Medical Economics Company, Inc., Montvale, NJ), which is E herein incorporated by reference. The active agents in the table below include their analogs, fragments, mimetics, and polyethylene glycol-modified derivatives.
Active Agent Disease and Physiological
Interferons, including a, B and y. [Viral infection, including chronic cancer and multiple sclerosis
Interleukin-1; interleukin-2.
Insulin; Insulin-like growth factor | Diabetes
IGF-1.
Heparin Thrombosis; prevention of blood coagulation
Calcitonin. Osteoporosis; diseases of the bone
Erythropoietin {pnemia 00000
Atrial naturetic factor
Monoclonal antibodies To prevent graft rejection; cancer
Somatostatin Bleeding ulcer; erosive gastritis [Protease imhibitors [amps
Active Agent Disease and Physiological
Adrenocorticotropin High cholesterol (to lower peenecorieomenin teen stimulate ovulation)
Oxytocin Labor disfunction (to stimulate :
Leutinizing-hormone-releasing- Regulate reproductive function hormone; follicle stimulating : a
Glucocerebrosidase Gaucher disease (to metabolize a rv
Filgrastim Reduce infection in
El ===
Parathyroid hormone (PTH), Osteoporosis; . Antimicrobials Infection including gram-— v7 ves veigt r= BR
Paget's disease; Inhibits osteoclasts . BIBN4096BS — (1- Anti-migraine; calcitonin gene-
Piperidinecarboxamide. N~[2-[ [ 5- | related peptide antagonist amino-1-{ [4-(4-pyridinyl)-1- piperazinyl)carbonyl]lpentyl] amino] - ha 1-[ (3,5~-dibromo-4- hydroxyphenyl) methyl] -2-oxoethyl]- 4(1,4-dihydro-2-oxo-3 (2H0- quinazolinyl)-. [R-(R*,5%)]-)
For example, one embodiment of the present invention is a method for treating a patient suffering from or susceptible to diabetes by administering insulin and at least one of the delivery agent compounds of the present invention.
Following administration, the active agent present in the composition or dosage unit form is taken up into the circulation. The biocavailability of the agent is readily ’ assessed by measuring a known pharmacological activity in blood, e.g. an increase in blood clotting time caused by )
heparin, or a decrease in circulating calcium levels caused by calcitonin. Alternately, the circulating levels of the active agent itself can be measured directly. ) 5 DESCRIPTION OF THE PREFERRED EMBODIMENTS
The following examples illustrate the invention without ’ limitation. All parts are given by weight unless otherwise indicated.
Proton nuclear magnetic resanance (*H NMR) analyses for the compounds listed below were conducted on a 300 MHz Bruker spectrometer using dimethyl sulfoxide (DMSO-dg) as the solvent unless otherwise indicated.
Liquid chromatograph/mass spectrometry (LC-MS) analyses were performed with an Agilent Technologies, LC/MSD 1100 (single quad) having the following parameters:
Mobile Phase A: 50:950:5 acetonitrile:water:acetic acid : (v/v/v)
Mobile Phase B: 950:50:5 acetonitrile:water:acetic acid (v/v/v)
Gradient Elution: 4 minute linear gradient 0-100% B; total time per injection is 11 minutes
Injection volume: 5ul :
Column: ZORBAX Rapid Resolution Cartridge, SB-C18, 2.1 x 30 mm, 3.5 um
Particle size, catalog # 873700-902
Column temp: 40° C
UV detection at 244 nm
MSD parameters:
Source: API-ES, positive polarity
Scan Parameters: :
Mass Range: 125.00-600.00
Fragmentor: 60 V :
Gain: 1.0 EMV
Threshold: 150
Spray Chamber:
Gas Temp. 350 deg. D
Drying Gas: 12.0 1/min ’ Neb. Pressure; 40 psig : VCap 4000V positive/negative : Example 1: Preparation of Compounds la: Preparation of Compound 2
A solution of 40% dimethylamine/water (30 mL, 26.9 g, 239 mmol) and ethanol (50 mL) was treated with a solution of 8- bromo-l-octanol (15.13 g, 72.3 mmol) and ethanol (20 mL), added dropwise over 10 minutes. The reaction mixture was stirred for 75 hours, diluted with ethyl acetate (80 mL) and washed with saturated sodium bicarbonate solution. The aqueous phase was extracted with ethyl acetate. The combined organic phases were washed with saturated sodium bicarbonate solution (50 mL) and brine (2 x 40 mL), dried over sodium sulfate, and concentrated. The 11.4 g of 8-dimethylamino-1- octanol, isolated as a yellow oil, was used as is.
A slurry of carsalam (10.80 g, 66.2 mmol), 8- dimethylamino-l-octanol (11.4 g, 65.8 mmol), triphenylphosphine (17.53 g, 66.8 mmol) and tetrahydrofuran © (40 mL) was treated with a solution of diisopropyl azodicarboxylate (13.0 mL, 13.35 g, 66.0 mmol) and tetrahydrofuran (20 mL), added dropwise over 25 minutes causing the temperature to rise to 50° C. The reaction mixture was allowed to cool back to 25° C and stirred for 40 hours.
The solution was treated with aqueous 2N NaOH (70 mL, 140 | . mmol) and warmed to 60° C for 180 minutes. The cooled reaction mixture was washed with ethyl acetate (2 x 50 mL). The A aqueous phase was acidified with 4% aqueous HCl to a pH slightly less than 0 and was washed with ethyl acetate (2 x 40 mL). The pH of the aqueous phase was raised to 9.5 upon treatment with solid sodium bicarbonate. The aqueous phase was extracted with methylene chloride (10 x 40 mL). The ' 5 combined methylene chloride extracts were dried over sodium sulfate and concentrated to give 0.6 g of product. The rest ) of the product was found in the earlier ethyl acetate extracts. These ethyl acetate layers were extracted with IN aqueous NaOH (4 x 30 mL). These 4 aqueous phases were combined, acidified to pH 0.7 with 4% aqueous HCl, and washed with ethyl acetate (2 x 30 mL). The pH of the aqueous - solution was adjusted to 5 with aqueous 2N NaOH. . The solution was treated with solid sodium bicarbonate until no more bubbling occurred and was extracted with ethyl acetate (6 x 50 mL). The combined ethyl acetate layers were dried over sodium sulfate and concentrated to a solid. The solid was taken up : into a tetrahydrofuran and treated with HCl gas. Water was added causing a solid to precipitate out of solution. A total of 4.73 g of N-(8-dimethylaminooctyl)salicylamide hydrochloride was isolated by filtration. m.p. 78-80° C; 'H NMR (DMSO—dg¢), S(ppm): 10.5 (bs, 1H), 8.9 (¢, 1H), 7.9 (dd, 1H), 7.4 (td, 1H), 6.9 (m, 2H), 3.3 (aq, 2H), 3.0 (m, 2H), 2.7 (s, 6H), 1.6 (t, 4H), 1.3 (m, 8H). KF value = 5.19% water. Elemental analysis: %C: 58.86 (calculated), 58.87 (found); %H: 9.01 (calculated), 8.98 (found); %N: 8.08 (calculated), 7.98 (found). 1b: Preparation of Compound 4
A one-neck, 250 mL round bottomed flask was charged with 4- (dimethylamino)benzylamine dihydrochloride (8.0 g, 0.0358 mol) and 50 mL of methylene chloride. The stirred solution was chilled in an ice bath. Triethylamine (20.0 mL, 0.1432 mol) and a catalytic amount of 4-(dimethylamino)pyridine (DMAP) were added to the reaction mixture. A solution of acetylsalicyloyl chloride (7.12 g, 0.1432 mol) in methylene chloride (30 mL) was added to the chilled reaction flask. :
After the addition was complete, the reaction mixture was warmed to room temperature and was allowed to stir overnight.
The reaction mixture was diluted with 2N HCl, and the ' layers were separated. The organic phase was washed with water, dried over sodium sulfate, and concentrated in vacuo.
The resulting oil was stirred in 2N NaOH for 4 hours, and washed with ethyl acetate. The aqueous phase was concentrated in vacuo to remove any residual ethyl acetate. The pH of the aqueous phase was adjusted to 7, and the resulting solids were collected by vacuum filtration. The weight of the crude solids was 1.76 g. The reaction was repeated to give an additional 0.88 g of crude product. The combined solids were recrystallized from ethanol/water to give 2.64 g of N-(4- dimethylaminobenzyl) salicylamide as a white solid. m.p. 129-132° C; *H NMR(de-DMSO), &(ppm): 9.3 (s, 1H), 7.87 (dd, 1H), 7.39 (dt, 1H), 7.16 (d, 2H), 6.87 (t, 2H), 6.69 (d, y 2H), 4.38 (d, 2H), 2.86 {(s, 6H). Elemental analysis: %C: 71.09 (calc.), 70.84 (found); %$H: 6.71 (calc.}, 6.50 (found); $N: 10.36 (calc.), 10.14 (found). lec: Preparation of Compound 5 .A suspension of morpholine (3.30 mL, 3.30 g, 37.8 mmol), 6-bromo-l-hexanol (6.72 g, 72.3 mmol), ethanol (20 mL), and : potassium carbonate (6.23 g, 45.1 mmol) was stirred for 36 hours at 25° C, after a slight exotherm at the beginning. The reaction mixture was diluted with ethyl acetate (30 nL), filtered and concentrated. The residue was taken up in ethyl acetate, filtered and concentrated. The 7.0 g of 4-(6- hydroxyhexyl)morpholine was isolated as a yellow oil and used . as is.
A slurry of carsalam (6.13 g, 37.6 mmol), 4-(6- :
hydroxyhexyl)morpholine (7.0 g, 37.4 mmol), triphenylphosphine (9.97 g, 35.0 mmol), and tetrahydrofuran (40 mL) was treated with a solution of diisopropyl azodicarboxylate (7.40 mL, 7.60 g, 37.6 mmol) and tetrahydrofuran (10 mL), added dropwise over
S 15 minutes. The reaction mixture was stirred at 25° C for 60 " hours. The solution was treated with aqueous 2N NaOH (50 mL, 100 mmol) and warmed to 60° C for 180 minutes. The cooled reaction mixture was concentrated to remove the ‘ tetrahydrofuran. The aqueous residue was washed with ethyl acetate (2 x 40 ml), and was acidified with 4% aqueous HCl to a pH of 0.84 (causing carbon dioxide gas to evolve). The pH of the aqueous phase was raised to 7.8 with 2N aqueous NaOH.
Solid sodium bicarbonate was added. Extraction with ethyl acetate (8 x 40 mL), drying over sodium sulfate and concentration gave an oil which solidified upon standing. A total of 4.26 g of 4-(6-morpholin-4-ylhexyl)-salicylamide was isolated. m.p. 70-73° C; 'H NMR(d¢-DMSO), &(ppm): 8.8 (t, 1H), 7.8 (dd, 1H), 7.4 (td, 1H), 6.9 (m, 2H), 3.5 (t, 4H), 3.3 (gq, 2H), 2.3 (t, 4H), 2.2, (t, 2H), 1.5 (t, 2H), 1.3-1.4 (m, 6H). KF value = 5.39 % water. Elemental analysis: %C: 63.05 (calculated), 63.06 (found); %H: 8.70 (calculated), 8.53 (found); %N: 8.65 {calculated}, 8.73 (found). . 2° 1d: Preparation of the Citrate Salts of Compounds 1,7 | )
Synthesis of N-Hydroxysuccimide-O-acetyl-5-chlorosalicylate 5-Chlorosalicylic acid (17.3 g, 100 mmol) and three drops of concentrated sulfuric acid (98%) were added to a solution of acetic anhydride (14 g, 137 mmol) and glacial acetic acid © (16.4 g, 274 mmol) with stirring. The reaction mixture was - slowly heated to 70 °C and stirred for 2 hours. The reaction mixture was cooled to room temperature and was gradually added to ice water (500 mL) to precipitate the acetylated product.
These solids were collected and washed with water. The two batches of product were combined and recrystallized in ethyl acetate. The pure crystals were collected via vacuum filtration to give 16.3 g of O-acetyl-5-chlorosalicylic acid (76 mmol, 76% yield).
Elemental analysis calculated for CgH,0,Cl: C 50.37%, H 3.29%,
N 0.0%; Found: C 50.36%, H 3.20%, N <0.02%. :
N-Hydroxysuccinimide (8.6g, 82 mmol) was dissolved in dimethyl formamide (DMF) (8 mL). This solution was mixed with : O-Acetyl-5-chlorosalicylic acid (16 g, 74.6 mmol) in dichloromethane (DCM) (150 mL) at room temp. This mixture was stirred in a water bath. 1,3-dicyclohexylcarbodiimide (DCC) (17 g, 82 mmol) was dissolved in dichloromethane (55 mL) and was gradually added to the mixture. The reaction equilibrated to room temperature and stirred for 24 hours. The mixture was cooled to -10° C and was filtered to remove any solids. The filtrate was diluted with dichloromethane (100 mL). The solution was washed with IN HCl (2 x 200 mL), brine (2 x 200 mL), 5% sodium bicarbonate (2 x 200mL) and brine (2 x 200 mb).
The dichloromethane layer was dried over anhydrous sodium sulfate. The solvent was evaporated in vacuo. The product was collected to give 22.5 g (72 mmol, 97%).
Compound 7: 2-(5-chloro-2-hydroxybenzoyl)amino-5- (N’ /N’- diethylamino) pentane mono-citrate
IUPAC name: N-[5-(diethylamino)-1l-methylpentyl]-5-chloro-2- hydroxybenzamide mono-citrate
N-Hydroxysuccimide-0-acetyl-5-chlorosalicylate obtained above (3.1 g, 10 mmol) was dissolved in dichloromethane (15 mL). This solution was slowly added to 2-amino-5- diethylaminopentane (3.2 g, 20 mmol) in dichloromethane (35 mL) with stirring. The reaction mixture was stirred overnight } at room temperature. HPLC indicated the completion of the reaction. The reaction mixture was washed with 5% sodium bicarbonate (3 x 100 mL). The organic layer was dried over anhydrous sodium sulfate. The dichloromethane evaporated in vacuo to give the free tertiary amine product (2.3 g, 7.4 ’ 5 mmol, 74%). - The above obtained 2-(5-chloro-2~hydroxybenzoylamino)-5-(N,N- diethylamino)pentane (2.3 g, 7.4 mmol) and citric acid (1.4 gs 7.4 mmol) were dissolved in anhydrous ethyl alcohol (8 mL).
Diethylether (~30 mL) was added to this solution until the solution became cloudy. The cloudy solution was refrigerated overnight to precipitate the citric acid salt. The final product, 2-(5-chloro-2-hydroxybenzoylamino)-5-(N,N- diethylamino) pentane mono-citrate, was collected via vacuum filtration and dried under nitrogen flow to give 2.0 g (4.0 mmol, 54%). : : m.p. 57-59°C; ‘HNMR (DMSO-ds) S(ppm): 1.18 (m, SH), 1.60 (m, 4H), 2.57 (4a, 4H), 3.08 (m, 6H), 4.04 (gq, 1H), 4.11 (s, 1H), 6.98 (d, 1H), 7.47 (dd, 1H), 8.01 (d, 1H), 8.70 (s, 1H). KF value = 0.59%. Elemental nalysis for calculated C,;H33N;00Cl:
C 52.33, H 6.54, N 5.55. Found: C 52.21, H 6.79, N 5.20.
Compound 1: N-(5-chloro-2-hydroxybenzoyl) -N’ N’ - diethylenediamine mono-citrate
IUPAC name: N-[2-(diethylamino)ethyl]-5-chloro-2- hydroxybenzamide mono-citrate
Compound 1 was prepared by the same procedure as for compound 7 with the appropriate starting materials. m.p. 107-109° C; HNMR (DMSO-ds), &(ppm): 1.16 (t, 6H), 2.61 (Qab, 4H), 3.09 (m, 6H), 3.59 (s, 2H), 6.98 (d, 1H), 7.44 (dd, 1H), 7.88 (d, 1H), 9.09 (s, 1H), 9.95-11.20 (s, 3H).
Elemental analysis for calculated C;9H27N,0,Cl: C 49.30, H 5.84, N 6.05; found: CC 49.30, H 5.78, N 5.94. le: Preparation of Compound 11,18 : 40 ’ Synthesis of N-Hydroxysuccimide-O-acetyl-4-methoxysalicylate
N-hydroxysuccimide-O-acetyl-4-methoxysalicylate was prepared by the same procedure as for N-hydroxy-O-acetyl-5- : chlorosalicylate with the appropriate starting materials. -
Compound 11: 8-(2-hydroxy-4-methoxybenzoylamido) octylamine hydrogen chloride :
IUPAC name: N-(8-aminooctyl)-2-hydroxy-4- methoxybenzamide hydrogen chloride * N-hydroxysuccimide-0O-acetyl-4-methoxysalicylate as obtained above (13 g, 42.3 mmol) was dissolved in dichloromethane (70 mL) and added dropwise to a solution of 1,8-diaminooctane (13 g, 90 mmol) in dichloromethane (230 mL) in a water bath with stirring. The reaction was stirred overnight. The product precipitated out of solution and was : collected via vacuum filtration. The precipitates were washed with dichloromethane and were air-dried to give 9.0 g of crude product. The precipitates were washed with water (50 mL) and extracted with 0.1N HCl agueous solution (50 mL) for 0.5 hours ’ with stirring. The acidic aqueous solution was filtered to remove insoluble material. The filtrate was washed with ethyl ether (150 mL) and was adjusted to pH 10. Precipitation occurred immediately. The mixture was allowed to stand at : room temperature over night. The precipitate was collected by filtration and air-dried to yield 2.6 g (8.8 mmol, 21%).
The free primary amine obtained above (1.7 g, 5.8 mmol) was suspended in 20 mL of anhydrous ethyl alcohol. HCl gas was bubbled into this mixture for 10 minutes to obtain a clear solution. Nitrogen gas was bubbled through this solution to purge the excess HCl and to evaporate the ethyl alcohol until : ~ the volume of the solution was 10 mL. This solution was refrigerated for 2 hours to precipitate the product. The . product was collected via vacuum filtration, was washed with ethyl ether and dried in vacuo to give 1.7 g of the :
hydrochloric salt (5.1 mmol, 89%). m.p. 162-164° C; HNMR (DMSO-d¢), S(ppm): 1.36 (s, 8H), 1.53 (m, 4H), 2.71 (sex, 2H), 3.22 (gq, 2H), 3.76 (s, 3H), 6.42 (m, 2H), 7.83 (4, 1H), 7.93-8.11 (s, 3H), 8.77 (t, 1H), 13.12 (bs, , 1H). Elemental analysis for calculated C;gHp7N,0sCl: C 58.08,
H 8.23, N 8.47; found: C 57.46, H 8.24, N 8.63. ) Compound 18: N-(2-hydroxy-4-methoxybenzoyl)-~1,8- diaminooctane
IUPAC name: N-[2-(diethylamino)ethyl]-2-hydroxy-4- methoxybenzamide
Compound 18 was prepared by the same procedure as for compound 11 with the appropriate starting materials. m.p.151-153° ¢; HNMR (DMSO-ds), &(ppm): 1.16-1.40 (m, 8H), 1.46 (m, 4H), 2.64 (t, 2H), 3.23 (s, 2H), 3.69 (s, 3H), 6.13 (d, 1H), 6.17 (s, 1H), 7.67 (d, 1H), 10.05 (s, 1H). KF value = 0.93%. Elemental analysis for calculated C;gH2gN203*0.16H>0:
C 64.67, H 8.86, N 9.43; found: C 64.26, H 8.84, N 9.65. 1f: Preparation of Citrate Salts of Compounds 3,6,8 and )
Compounds 9,10,17
Synthesis of N-Hydroxysuccimide~O-acetylsalicylate
N-Hydroxysuccinimide (12 g, 104 mmol) was dissolved in DMF (15 mL). This solution was mixed with O-acetylsalicoyl chloride (20 g, 101 mmol) in dichloromethane (150 mL) at room temperature. Triethylamine (11 g, 109 mmol) was added dropwise to this mixture with stirring. The reaction mixture was stirred for 2 hours. The mixture was filtered to remove any insoluble material. The filtrate was collected and the solvents were evaporated in vacuo. The resulting oil was dissolved in 200 mL of ethyl acetate. Any remaining solids were removed by filtration. The filtrate was washed with 1N . HCl (3 x 150 mL), brine (1 x 150 mL), 4% sodium bicarbonate (3 40 x 150 mL) and brine (1 x 150 mL). The ethyl acetate layer was dried over anhydrous sodium sulfate. Ethyl acetate was removed by vacuum evaporation, followed by a nitrogen purge. 20 g (72 mmol, 72%) of N-hydroxysuccimide-O-acetylsalicylate was produced.
Compound 3: N- (2-hydroxybenzoyl) ~N’ ,N’ -diethylenediamine mono- citrate
IUPAC name: N-[2-{diethylamino)ethyl]-2-hydroxybenzamide mono—citrate
Compound 3 was prepared by the same procedure as for compound 7 with the appropriate starting materials. m.p. 111-113° C; HNMR (DMSO-ds), &(ppm): 1.17 (t, 6H), 2.59 (gab, 4H), 3.09 (m, 6H), 3.61 (g, 2H), 6.95 (m, 2H), 7.44 (t, 1H), 7.85 (d, 1H), 9.07 (s, 1H), 10.25 (bs, 2H). KF value= 0.30%. Elemental analysis for calculated C;gH;gN209: C 53.27,
H 6.54, N 6.54; found: C 52.96, H 6.28, N 6.37. 2- (2-hydroxybenzoyl) amino-5- (N,N-diethylamino) pentane mono- } citrate '
IUPAC name: N-[5-(diethylamino)-l-methylpentyl]-2- hydroxybenzamide mono-citrate 2-(2-hydroxybenzoyl)amino-5-(N,N-diethylamino)pentane mono- citrate was prepared by the same procedure as for compound 7 with the appropriate starting materials. . m.p. 62-64° C; HNMR (DMSO-ds), &(ppm): 1.18 (m, 9H), 1.61 (m, 4H), 2.57 (Qap, 4H), 3.02 (m, 6H), 4.03 (q, 1H), 4.11 (s, 1H), 6.91 (m, 2H), 7.41 (t, 1H), 7.89 (d, 1H), 8.58 {s, 1H), 10.6- 11.8 (s, 2H). Elemental analysis for calculated C;;H34N209: Cc 56.17, H 7.23, N 5.96; found: C 55.77, H 7.35, N 5.71.
Compound 8: N- (2-hydroxybenzoyl) -N’ ,N’ -di (n-butyl) -1,3- diaminonopropane mono-citrate
IUPAC name: N-{3-([dibutylamino]propyl}-5-chloro-2- . hydroxybenzamide mono-citrate 40 - The procedures were the same as those described for Compound 7 except for the starting materials. m.p. 87-89° C; 'HNMR (DMSO-ds), &(ppm): 0.89 (t, 6H), 1.30
(sex, 4H), 1.53 (m, 4H), 1.77 (quin, 2H), 2.59 (Qu, 4H), 2.84- 3.04 (m, 6H), 3.36 (t, 2H), 6.96 (d, 1H), 7.44 (dd, 1H), 7.90 (d, 1H), 8.97 (s, 1H). Elemental analysis for calculated
C19H27N204C1: C 54.08, H 6.95, N 5.26; found: C 54.13, H 7.00,
N 5.10.
Compound 9: N- (2-hydroxybenzoyl) -1,12-diaminododecane hydrogen chloride . IUPAC name: N-(l2-aminododecanyl)-2-hydroxybenzamide hydrogen chloride
Compound 9 was prepared by the same procedure as for compound 7 with the appropriate starting materials. m.p. 140-142° C; HNMR (DMSO-ds), &(ppm): 1.21 (s, 16H), 1.53 (m, 4H), 2.72 (sex, 2H), 3.27 (gq, 2H), 6.89 (m, 2H), 7.31 (t, 1H), 7.7.91 (4, 1H), 7.96-8.20 (s, 3H), 8.93 (s, 1H), 12.87 (s, 1H). Elemental analysis for calculated CjoH33N,0,Cl: C 63.94, H 9.32, N 7.85, Cl 9.93; found: CC 63.33, H 9.45, N, 7.28, C1 10.87.
Compound 10: 10-(2-hydroxybenzoylamido) decylamine hydrogen chloride :
IUPAC name: N-(l0-aminodecyl)-2-hydroxybenzamide hydrogen ’ chloride
Compound 10 was prepared by the same procedure as for compound 11 with the appropriate starting materials. m.p. 136-138° C; HNMR (DMSO-dg), &(ppm): 1.24 (s, 12H), 1.51 (m, 4H), 2.71 (t, 2H), 3.26 (gq, 2H), 6.87 (m, 2H), 7.37 (t, - 1H), 7.88 (d, 1H), 7.89-8.13 (s, 3H), 8.91 (t, 1H), 12.76 (s, 1H). Elemental analysis for calculated C37H29N20,Cl: C 62.09,
H 8.89, N 8.52; found: C 60.66, H 9.11, N 8.73.
Compound 17: N-(2-hydroxybenzoyl)-1,9-diaminononane
JUPAC name: N-{(8-aminononyl)-2-hydroxybenzamide 40 Compound 17 was prepared by the same procedure as for preparing the free amine of compound 11 with the appropriate starting materials.
HNMR (DMSO-ds), &(ppm): 1.21-1.42 (m, 12E), 1.51 (m, 2H), 45 2.60 (t, 2H), 3.27 (t, 2H), 6.63 (t, 1H), 6.70 (d, 1H), 7.22
(t, 1H), 7.78 (d, 1H), 9.80 (s, 1H). KF value= 0.91%.
Elemental analysis for calculated CigHa6N,0, (0.91% H0): C 68.61, H 9.33, N 9.97; Found: C 68.54, H 9.41, N 10.31. . 1g: Preparation of Compound 12
A 20 mL scintillation vial was charged with 3,5- : dibromosalicylic acid (1.299 g, 4.39 mmol), 1-[3- (dimethylamino) propyl]-3-ethylcarbodiimide*HC1 (0.99 g, 5.2 ~ mmol) and l-hydroxybenzotriazole hydrate (0.79 g, 5.8 mmol). 1-(3-Aminopropyl)imidazole (476 pl, 3.99 mmol) was added by autopipet. THF (10 mL) was added, the vial was capped, and placed on an orbital shaker overnight at 60°C. The heat was turned off and the vial was allowed to cool back to room temperature. Trisamine resin (200 mg, 0.85 mmol) was added and the vial placed back on the orbital shaker for 4 hours.
Amberlyst-15 (2 g, 9.4 mmol) and Amberlyst-21 (2 g, 9.4 mmol) ion-exchange resins were added to the vial along with DCM (5 . mL) to suspend the resins. The vial was placed back on the orbital shaker overnight. The reaction mixture was filtered ) and the resins wére rinsed with DCM (2 x 5 mL). The combined filtrates were placed under a nitrogen stream overnight. 2.3985 g of material was recovered.
LC-MS: rt = 2.39 min, 89 $, M + H = 404. 1h: Preparation of Compound 13 © A 20 mL scintillation vial was charged with 3,5- dichlorosalicylic acid (0.9082 g, 4.39 mmol), 1-[3~ (dimethylamino) propyl] -3-ethylcarbodiimide*HC1 (0.99 a, 5.2mmol) and l-hydroxybenzotriazole hydrate (0.79 g, 5.8 mmol). 1-(3-Aminopropyl)imidazole (476 pl, 3.99 mmol) was : added by autopipet. THF (10 mL) was added, the vial was i capped, and placed on an orbital shaker overnight at 60°C. .
The heat was turned off and the vial was allowed to cool back to room temperature. Trisamine resin (200 mg, 0.85 mmol) was . added and the vial placed back on the orbital shaker for 4 hours. Amberlyst-15 (2 g, 9.4 mmol) and Amberlyst-21 (2 g, 9.4 mmol) ion-exchange resins were added to the vial along © with DCM (5 mL) to suspend the resins. The vial was placed back on the orbital shaker overnight. The reaction mixture ' "5 was filtered and the resins were rinsed with DCM (2 x 5 mL).
The combined filtrates were placed under a nitrogen stream ) overnight. 2.0343 g of material was recovered.
LC-MS: rt = 2.24 min, 79%, M + H = 315 1i: Preparation of Compound 14
A 20 mL scintillation vial was charged with 3,5- diiodosalicylic acid (1.700. g, 4.39 mmol), 1-[3- (dimethylamino) propyl] -3-ethylcarbodiimide*HC1l (0.99 g, 5.2 mmol) and l-hydroxybenzotriazole hydrate (0.79 g, 5.8 mmol). 1-(3-Aminopropyl) imidazole (476 pl, 3.99 mmol) was added by autopipet. THF (10 mL) was added, the vial was capped, and placed on an orbital shaker overnight at 60° C. The heat was turned off and the vial was allowed to cool back to room temperature. Trisamine resin (200 mg, 0.85 mmol) was added and the vial placed back on the orbital shaker for 4 hours.
Amberlyst-15 (2 g, 9.4 mmol) and Amberlyst-21 (2 g, 9.4 mmol) ion-exchange resins were added to the vial along with DCM (5 mL) to suspend the resins. The vial was placed back on the orbital shaker overnight. The reaction mixture was filtered and the resins were rinsed with DCM (2 x 5 mL). The combined filtrates were placed under a nitrogen stream overnight. 2.7305 g of material was recovered.
LC-MS: rt = 2.62 min, 84 %, M + H = 498 1j: Preparation of Compound 15 :
A 20 mL scintillation vial was charged with 3,5-~ dibromosalicylic acid (1.299 g, 3.8 mmol), 1-[3- (dimethylamino) propyl]-3-ethylcarbodiimide*HCl (0.84 g, 4.39 mmol) and l-hydroxybenzotriazole hydrate (0.59 g, 4.38 mmol). 4~ (3-Aminopropyl)morpholine (506 pl, 3.47 mmol) was added by autopipet. THF (10 mL) was added, the vial was capped, and placed on an orbital shaker overnight at 60° C. The heat was turned off and the vial was allowed to cool back to room temperature. Trisamine resin (200 mg, 0.85 mmol) was added and the vial placed back on the orbital shaker for 4 hours. :
Amberlyst-15 (2 g, 9.4 mmol) and Amberlyst-21 (2 g, 9.4 mmol) ion-exchange resins were added to the vial along with DCM (5 mL) to suspend the resins. The vial was placed back on the . orbital shaker overnight. The reaction mixturé was filtered and the resins were rinsed with DCM (2 x 5 mL). The combined filtrates were placed under a nitrogen stream overnight. 2.103 g of material was recovered.
LC-MS: rt = 2.36 min, 74%, M + H = 423 1k: Preparation of Compound 16 :
A 20 mL scintillation vial was charged with 3,5- dichlorosalicylic acid (0.786 g, 3.8 mmol), 1-[3- (dimethylamino) propyl} -3-ethylcarbodiimide*HCl (0.84 g, 4.39 mmol) and 1-hydroxybenzotriazole hydrate (0.59 g, 4.38 mmol). 4~ (3-Aminopropyl)morpholine (506 ul, 3.47 mmol) was added by : autopipet. THF (10 mL) was added, the vial was capped, and : placed on an orbital shaker overnight at 60° C. The heat was turned off and the vial was allowed to cool back to room temperature. Trisamine resin (200 mg, 0.85 mmol) was added and the vial placed back on the orbital shaker for 4 hours. © Amberlyst-15 (2 g, 9.4 mmol) and Amberlyst-21 (2 g, 9.4 mmol) ion-exchange resins were added to the vial along with DCM (5 mL) to suspend the resins. The vial was placed back on the : orbital shaker overnight. The reaction mixture was filtered - : and the resins were rinsed with DCM (2 x 5 mL). The combined filtrates were placed under a nitrogen stream overnight. ' -3 0 _
h 1.648 g of material was recovered.
LC-MS: rt = 2.23 min, 75%, M + H = 334 lk: Alternate preparations of Compounds 12,13,14,15,16
Compounds 12, 13, 14, 15, and 16 are synthesized by the same procedure described to make compound 7 using the ’ appropriate starting materials.
Example 2 2A: Insulin - Oral Delivery .
Oral dosing (PO) compositions of delivery agent compound and human zinc insulin (minimum 26 IU/mg available from
Calbiochem - Novabiochem Corp, La Jolla, CA) were prepared in : deionized water. Typically, 500 mg of delivery agent compound was added to 1.5 ml of water. The solution was vortexed, then heated (about 37°C) and sonicated. The pH was adjusted to about 7 to 8.5 with NaOH or HCl. Additional NaOH was added, if necessary, to achieve uniform solubility, and the pH re- adjusted to about 7 to 8.5. Water was then added to bring oo the total volume to about 2.4 ml and vortexed. About 1.25 mg insulin from an insulin stock solution (15 mg/ml made from 0.5409 g insulin and 18 ml deionized water, adjusting with HCl and NaOH to pH 8.15 and to obtain a clear solution using 40 ml concentrated HCl, 25 ml 10N NaOH and 50 ml 1N NaOH) was added to the solution and mixed by inverting. The solution may be used in the dosing protocol immediately, or alternatively, the solution may be placed into a 37°C water bath for one hour prior to dosing. The final delivery agent compound dose, insulin dose and dose volume amounts are listed below in Table 1. oo
The typical dosing and sampling protocols were as follows. Male Sprague-Dawley rats weighing between about 200- 250g were fasted for 24 hours and administered ketamine (44 mg/kg) and chlorpromazine (1.5 mg/kg) 15 minutes prior to dosing and again as needed to maintain anesthesia. A dosing ' group of five animals was administered one of the dosing solutions. For oral dosing, an 11 cm Rusch 8 French catheter was adapted to a 1 ml syringe with a pipette tip. The syringe oo was filled with dosing solution by drawing the solution through the catheter, which was then wiped dry. The catheter was placed down the esophagus leaving 1 cm of tubing past the incisors. The dosing solution was administered by pressing the syringe plunger.
Blood samples were collected serially from the tail : artery, typically at time = 15, 30, 60, 120 and 180 minutes.
Serum insulin levels were determined with ah Insulin ELISA :
Test Kit (Kit # DSL~10-1600 from Diagnostic Systems
Laboratories, Inc., Webster, TX), modifying the standard protocol in order to optimize the sensitivity and linear range of the standard curve for the volumes and concentrations of ’ the samples used in the present protocol. Serum human insulin concentrations (pU/ml) were measured for each time point for each of the five animals in each dosing group. The five values for each time point were averaged and the results plotted as serum insulin concentration versus time. (Previous ~ experiments revealed no measurable levels of human insulin following oral dosing with human insulin alone.) The maximum (peak) and the area under the curve (AUC) are reported below in Table 1.
Table 1. Insulin - Oral Delivery : —- 3 2 -—
El LN
Agent Agent Dose dose Serum [INS]
Compound Compound | (mg/kg) (ml/kg) + SD
Dose (mg/kg) 2B: Biotinylated Ribonuclease A (bRNase A) Oral Delivery : Oral gavage (PO) dosing solutions of delivery agent compound and bRNase A (Sigma (Milwaukee, WI): Ribonuclease A
Type XII-A from bovine pancreas) in deionized water were prepared by mixing. The delivery agent compound solution was prepared in phosphate buffer and stirred. If necessary, the pH of the mixture was adjusted upwards by the addition of aliquots of NaOH of an appropriate normality until the delivery agent compound was completely dissolved. The final pH of the dissolved delivery agent compound was between 7.5 and 9.5. The final dosing solutions were prepared by mixing 9 volumes of the delivery agent compound solution with 1 volume of a bRNase A stock solution (20 mg bRNase A in phosphate buffered saline (PBS)). Final concentrations were 150 mg/ml delivery agent compound and 2 mg/ml bRNase A.
The dosing and sampling protocols were as follows. Male
Sprague-Dawley rats weighing 200-250 g were fasted for 24 hours and administered ketamine (44 mg/kg) and chlorpromazine (1.5 mg/kg) 15 minutes prior to dosing and again as needed to . maintain anesthesia. A dosing group of five animals was administered one of the dosing solutions in the following manner. An 11 cm Rusch 8 French catheter was adapted to a 1 ml syringe with a pipette tip. The syringe was filled with dosing solution by drawing the solution through. the catheter, which was then wiped dry. The catheter was placed down the esophagus leaving 1 cm of tubing past the incisors. The dosing solution was administered by pressing the syringe plunger. Blood samples were collected serially from the tail artery at 15, 30, 45, 60 and 90 minutes. Serum bRNase A concentrations were quantified by a modified immunoassay as ‘ described below.
Biotinylation of Ribonuclease A
To label each of the RNase 'A molecules with one biotin molecule, the ratio of the activated biotin was maintained at 3 moles biotin/ 1 mole RNase A. In a representative biotinylation reaction 500 mg of RNase A was dissolved in 20 ml of 50 mM NaHCO;, pH 7.6. 57.08 mg of EZ-Link Sulfo-NHS-LC-
IC Biotin (Pierce Chemical Company, Rockford, IL) was added to the solution, dissolved and allowed to stand on ice for 2 hours. The reaction mix was then dialyzed (10,000 MW cutoff : dialysis membrane (Pierce, Rockford, Illinois)) against 4 liters of PBS at 4° C. overnight. The reaction mix was place in 4 liters of fresh PBS and dialyzed for an additional 4 hours. The dialyzed bRNase A was removed from the dialysis membrane, diluted to a final volume of 25 ml with PBS (final concentration of bRNase A = 20 mg/ml), and stored a 4° c.
Assay of Serum Levels of Orally Administered bRNase A
In general 100 pl aliquots of the rat sera collected at the various time points were placed in the appropriate wells of a 96 well Reacti-Bind Streptavidin Coated Polystyrene
Plates (Pierce). After a 2 hour incubation period the plates ) were washed and then incubated with a polyclonal rabbit anti-
RNase A (Chemicon, Pittsburgh, PA). After washing, the plates were incubated for 2 hours with a polyclonal goat anti-rabbit :
IgG (Chemicon, Pittsburgh, PA) conjugated to alkaline phosphatase. The plates were washed after the incubation and :
the amount of initially captured bRNase A is detected by the addition of para-nitrophenyl phosphate (a substrate for alkaline phosphatase) ( Pierce, Rockford, Illinois). The amount of bRNase A circulating in the original rat sera is ' 5 quantitated by comparison with a standard curve of bRNAse A which extends from 1000 - 0.1 ng/mL in fifteen two-fold ' dilutions. The maximum + standard deviation is given in Table 2 below.
Table 2 — Oral Delivery of RNAase
EL tl
Agent Agent Dose dose Serum ng/ml . Compound Compound | (mg/kg) (ml/kg)
Dose (mg/kg) : 2c: Oral Delivery of BIBN4096BS
Oral gavage (PO) dosing solutions of delivery agent compound and the Calcitonin gene-related peptide antagonist, 1-Piperidinecarboxamide. N-[2-[ [ 5-amino-1-{ [4-(4- pyridinyl)-1-piperazinyl)carbonyl]pentyl]amino]-1-[ (3,5- dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4 (1, 4-dihydro-2- . 0x0-3(2H0-quinazolinyl)-. [R~(R*,S*)]- (BIBN40S6RBS) in water were prepared. Typically, a solution of the delivery agent - 25 compound was prepared in water and stirred. The final dosing solutions were prepared by mixing the delivery agent compound with a BIBN4096BS stock solution and diluting to the desired volume (usually 1.0 mL). If necessary, the pH ¢£ the mixture was adjusted by the addition of aliquots of aqueous hydrochloric acid solution of an appropriate normality until the final pH of the dosing solution was below 7.0. The final compound amounts per dose were 25 mg/kg of BIBN4096B3, 200 mg/kg of delivery agent compound, in a total volume of ImL/kg.
The typical dosing and sampling protocols were as follows. Male Sprague-Dawley rats weighing between 200-250g were fasted for 24 hours and administered ketamine (44 mg/kg) : and chlorpromazine (1.5 mg/kg) 15 minutes prior to dosing. A dosing group of five rats was administered one of the dosing solutions. For oral gavage (PO) dosing, an 11 cm Rusch 8
French catheter was adapted to a 1 mL syringe with a pipette tip. The syringe was filled with dosing solution by drawing the solution through the catheter, which was then wiped dry.
The catheter was placed down the esophagus leaving 1 cm of } tubing past the incisors. Solution was administered by pressing the syringe plunger. Blood samples were collected serially from the tail artery, typically at time = 0, 15, 30, 45, and 60 minutes for oral. Plasma BIBN4096BS concentrations were quantified by using a liquid chromatography/mass spectrometry/mass spectrometry assay method using UV detection. The standard range for the assay was 5-2,000 ng/mL. :
Previous studies indicated baseline values of about 10 ng/mL.
The maximum is reported below in Table 3. ~ Table 3. Oral BIBN4096BS Delivery
. Delivery Delivery |{BIBN4096BS| Volume Mean Peak
Agent Agent Dose dose Serum ng/ml
Compound Compound (mg/kg) (ml/kg)
Dose (mg/kg) 78 10 «+ [ 200 | 25 [1 | 23 + 14 453 + 300° : 102 + 608" 122 3.6 15 | 200 [| 2s | 1 | o 15 2 0.1 * some dosing solutions were at a pH28.0 .
The above mentioned patents, applications, test methods, and publications are hereby incorporated by reference in their entirety.
Many variations of the present invention will suggest : themselves to those skilled in the art in light of the above detailed description. All such obvious variations are within the fully intended scope of the appended claims.
Claims (1)
- WHAT IS CLAIMED IS:: 1. A compound selected from the group consisting of compounds 1-18: OH © dd NN ’ H Cl rd Compound 1 OH © CY H ’ Compound 2 OH © r NNN ’ H Compound 3 OH O . SERS! H N~ Compound 4 ‘ OH 0 [oo OY tH Compound 5OH O a oh loo N H’ . Compound 6 Pi I (7 N._~ . HCl . . Compound 7 OH O - H ~ Compound 8 oH Q CY cl N Compound 9 : OH O oy ASSN CE N H Compound 10OH O H ~o ‘ Compound 11 OH © B ASA Ra H —/ Br : : Compound 12OH O RSARaE H \—/ cl Compound 13 OH O ASA RS H \—/ I - Compound 14 oH oO | : Br NTN Ld Br Compound 15 .: H O Cl AST N N U0 0}Cl . Compound 16Q . VN a CL - OH Compound 175 . OH O NSN SSN,H . Ie Compound 18 and salts thereof.2. A composition comprising: (A) an active agent; and {B) at least one compound of claim 1.3. The composition of claim 2, wherein the active agent is selected from the group consisting of a biologically active agent, a chemically active agent, and a combination thereof.4. The composition of claim 3, wherein the biologically active agent comprises at least one protein, polypeptide, peptide, hormome, polysaccharide, mucopolysaccharide, carbohydrate, or lipid. —- 4 1 —5. The composition of claim 3, wherein the biologically active agent is selected from the group consisting of: BIBN-4096BS, growth hormones, human growth hormones recombinant human growth hormones (rhGH), bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, ' interferons, o-interferon, B-interferon, y-interferon, interleukin-1, interleukin-2, insulin, porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor (IGF), IGF-1, heparin, unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin, human calcitonin; erythropoietin (EPO), atrial naturetic ) factor, antigens, monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone- . releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim. postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), fragments of PTH, antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol (PEG)-modified derivatives of these compounds; and any combination thereof.:6. The composition of claim 3, wherein the biologically ’ active agent comprises insulin, BIBN-4096BS, calcitonin, parathyroid hormone, erythropoietin, growth hormones or )combinations thereof.7. The composition of claim 3, wherein the biologically active agent comprises BIBN-4096BS. , 58. The composition of claim 3, wherein the biologically active agent comprises insulin.9. A dosage unit form comprising: (A) the composition of claim 2; and (B) (a) an excipient (b) a dilutent (c) a disintegrant, {d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof.10. The dosage unit form of claim 9, wherein the active agent is selected from the group consisting of a biologically active agent, a chemically active agent, and a combination thereof.11. The dosage unit form of claim 10, wherein the biologically active agent comprises at least one protein, : polypeptide, peptide, hormone, polysaccharide, mucopolysaccharide, carbohydrate, or lipid.12. The dosage unit form of claim 10, wherein the biologically active agent is selected from the group consisting of: BIBN-4096BS, growth hormones, human growth hormones (hGH), recombinant human growth hormones (rhGH),bovine growth hormones, porcine growth hormones, growth hormone releasing hormones, growth hormone releasing factor, interferons, oa-interferon, PB-interferon, y- interferon, interleukin-1, interleukin-2, insulin, 5S porcine insulin, bovine insulin, human insulin, human recombinant insulin, insulin-like growth factor, insulin- like growth factor-1l, heparin, unfractionated heparin, heparinocids, dermatans, chondroitins, low molecular : weight heparin, very low molecular weight heparin, ultra "low molecular weight heparin, calcitonin, salmon : . calcitonin, eel calcitonin, human calcitonin; erythropoietin, atrial naturetic factor, antigens, : monoclonal antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoeitin, filgrastim. postaglandins, cyclosporin, vasopressin, cromolyn sodium, sodium chromoglycate, disodium chromoglycate, vancomycin, desferrioxamine, parathyroid hormone, fragments of PTH, antimicrobials, anti-fungal agents, vitamins; analogs, fragments, mimetics and polyethylene glycol-modified derivatives of these compounds; and any combination thereof.13. The dosage unit form of claim 10, wherein the biologically active agent comprises insulin, BIBN-4096BS, calcitonin, parathyroid hormone, erythropoietin, human growth hormones or combinations thereof. ’ 30 14. The dosage unit form of claim 9, wherein the active agent comprises recombinant BIBN-4096BS.15. The dosage unit form of claim 9, wherein the active< + agent comprises insulin.16. The dosage unit form of claim 9, wherein the dosage unit form comprises a dosing vehicle comprising a tablet, a capsule, a powder, or a liquid.17. The dosage unit form of claim 9. wherein the dosing : vehicle is liquid selected from the group consisting or water, 1,2-propane diol, ethanol, and any combination18. The composition as claimed in claim 3 for use in orally administering a biologically active agent to an animal in need of the agent.19. A method for preparing a composition comprising mixing: (A) at least one active agent; (B) the compound of claim 1; and (C) optionally, a dosing vehicle.20. A method of preparing a compound substantially as herein described in Example 1 without reference to the specific quantities. - 45 - AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27272601P | 2001-03-01 | 2001-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200305569B true ZA200305569B (en) | 2004-04-08 |
Family
ID=23041002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200305569A ZA200305569B (en) | 2001-03-01 | 2003-07-18 | Compounds and compositions for delivering active agents. |
Country Status (2)
Country | Link |
---|---|
CA (1) | CA2356201A1 (en) |
ZA (1) | ZA200305569B (en) |
-
2001
- 2001-08-30 CA CA002356201A patent/CA2356201A1/en not_active Abandoned
-
2003
- 2003-07-18 ZA ZA200305569A patent/ZA200305569B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2356201A1 (en) | 2002-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7700775B2 (en) | Compounds and compositions for delivering active agents | |
US7297794B2 (en) | Phenoxy amine compounds and compositions for delivering active agents | |
EP1322595B1 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
US7125910B2 (en) | Compounds and compositions for delivering active agents | |
AU2002245580A1 (en) | Compounds and compositions for delivering active agents | |
US6693208B2 (en) | Compounds and compositions for delivering active agents | |
JP4975201B2 (en) | Compositions for delivering compounds and active agents | |
EP1163209A1 (en) | Compounds and compositions for delivering active agents | |
US20030216287A1 (en) | Compounds and compositions for delivering active agents | |
WO2002015959A2 (en) | Compounds and compositions for delivering active agents | |
ZA200305569B (en) | Compounds and compositions for delivering active agents. | |
WO2005062874A2 (en) | Compounds and compositions for delivering active agents | |
JP5215977B2 (en) | Compositions for delivering compounds and active agents |